January 14, 2025
Keio University School of Medicine
Keio University Hospital
Fujita Health University
A research group led by Project Professor Shigeto Shimmura (at the time of the research; currently a visiting professor at the Department of Ophthalmology, Keio University School of Medicine, and a professor at the Department of Clinical Regenerative Medicine, Fujita Health University) and Senior Assistant Professor Masatoshi Hirayama (at the time of the research; currently an associate professor at the same department) has conducted a clinical study as a Type 1 Regenerative Medicine Provision Plan to evaluate the safety and efficacy of a novel treatment for bullous keratopathy, an intractable disease. This treatment involves transplanting iPS cell-derived corneal endothelial cell substitutes into the anterior chamber of the eye. The results of this study were published in the scientific journal Cell Reports Medicine on January 13, 2025 (U.S. time).
Please see below for the full press release.